A drug and, more particularly, to a drug for treating inflammatory and dysimmune response. The present invention also relates to a drug for treating graft-versus-host disease. Thus, the present invention relates in particular to a cell expressing CD33, CD11b, CD14, CD163, CD206, HLA-DR, CD44, CD31, CCR5 and CD105.